Moxetumomab pasudotox

Drug Profile

Moxetumomab pasudotox

Alternative Names: CAT-8015; GCR-8015; HA22

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer MedImmune; National Cancer Institute (USA)
  • Class Antineoplastics; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action CD22 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hairy cell leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hairy cell leukaemia
  • Phase II Acute lymphoblastic leukaemia
  • Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 07 Jul 2017 AstraZeneca announces intention to submit regulatory application to US FDA for Hairy cell leukaemia in 2018 (AstraZeneca pipeline, July 2017)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Acute-lymphoblastic-leukaemia(In adolescents, In children, In infants, Second-line therapy or greater, In adults) in Canada (IV, Infusion)
  • 04 Feb 2016 Moxetumomab pasudotox receives Orphan Drug status for Hairy cell leukaemia in USA (AstraZeneca's pipeline, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top